ImmunoCellular Therapeutics (IMUC) 10-K 9 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Feb. 28, 2017	Jun. 30, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	ImmunoCellular Therapeutics, Ltd.
Entity Central Index Key	822,411
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Trading Symbol	IMUC
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 21,419,090
Entity Common Stock, Shares Outstanding		3,459,859

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 11,437,118	$ 22,604,481
Supplies for clinical trials	1,186,186	1,158,632
Other assets	791,485	797,425
Total current assets	13,414,789	24,560,538
Property and equipment, net	109,823	180,922
Supplies for clinical trials	1,309,648	1,115,657
Deposits	1,955,514	4,176,280
Deferred financing costs	100,216	48,977
Total assets	16,889,990	30,082,374
Current liabilities:
Accounts payable	1,342,126	1,161,258
Accrued compensation and benefits	1,109,864	790,487
Accrued liabilities	786,953	317,653
Total current liabilities	3,238,943	2,269,398
CIRM liability	6,945,741	4,133,905
Warrant Liability	573,560	1,958,775
Total liabilities	10,758,244	8,362,078
Commitments and contingencies (Note 5)
Shareholders’ equity:
Preferred stock $0.0001 par value, 1,000,000 shares authorized; 0 shares outstanding as of December 31, 2016 and December 31, 2015	0	0
Common stock, $0.0001 par value; 25,000,000 shares authorized as of December 31, 2016 and 2015 respectively; 3,444,859 and 2,257,718 shares issued and outstanding as of December 31, 2016 and December 31, 2015, respectively	344	225
Additional paid-in capital	102,354,844	95,857,811
Accumulated deficit	(96,223,442)	(74,137,740)
Total shareholders’ equity	6,131,746	21,720,296
Total liabilities and shareholders’ equity	$ 16,889,990	$ 30,082,374

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in usd per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	25,000,000	25,000,000
Common stock, shares issued (in shares)	3,444,859	2,257,718
Common stock, shares outstanding (in shares)	3,444,859	2,257,718

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Revenues	$ 0	$ 0	$ 0
Expenses:
Research and development	19,105,727	10,896,591	5,969,182
General and administrative	5,006,398	4,616,500	3,889,359
Total expenses	24,112,125	15,513,091	9,858,541
Loss before other income (expense) and taxes	(24,112,125)	(15,513,091)	(9,858,541)
Interest income	24,381	19,863	13,917
Interest expense	(1,311,836)	(133,905)	0
Financing expense	(498,520)	(88,939)	(62,683)
Change in fair value of warrant liability	3,812,398	2,925,258	529,774
Loss before taxes	(22,085,702)	(12,790,814)	(9,377,533)
Taxes	0	0	0
Net loss	$ (22,085,702)	$ (12,790,814)	$ (9,377,533)
Net loss per share (in usd per share)	$ (7.89)	$ (5.87)	$ (6.26)
Weighted average number of shares outstanding basic and diluted (in shares)	2,798,881	2,180,092	1,497,877

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($)	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning Balance at Dec. 31, 2013	$ 26,473,594	$ 144	$ 78,442,843	$ (51,969,393)
Beginning balance (in shares) at Dec. 31, 2013		1,438,520
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options	$ 1,045,000	$ 2	1,044,998
Exercise of stock options (in shares)	15,601	23,750
Cashless exercise of stock options		$ 0	0
Cashless exercise of stock options (in shares)		712
Stock based compensation	$ 654,260	$ 0	654,260
Common stock issued through controlled equity offering, in 2016 at an average price of $10.00 per share, and 2014 at $36.80 per share	4,496,322	$ 13	4,496,309
Common stock issued through controlled equity offering, in 2016 at an average price of $10.00 per share, and 2014 at $36.80 per share (in shares)		127,103
Net loss	(9,377,533)			(9,377,533)
Ending Balance at Dec. 31, 2014	23,291,643	$ 159	84,638,410	(61,346,926)
Ending balance (in shares) at Dec. 31, 2014		1,590,085
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options	$ 6,750	$ 0	6,750
Exercise of stock options (in shares)	1,250	625
Common stock and warrants issued for cash during August 2016 and February 2015, at $6.40 and $24.00 per unit, respectively, net of offering costs	$ 10,296,689	$ 66	10,296,623
Common stock and warrants issued for cash during August 2016 and February 2015, at $6.40 and $24.00 per unit, respectively, net of offering costs (in shares)		666,250
Cashless exercise of stock options		$ 0	0
Cashless exercise of stock options (in shares)		258
Stock based compensation	916,028		916,028
Stock based compensation (in shares)		500
Net loss	(12,790,814)			(12,790,814)
Ending Balance at Dec. 31, 2015	$ 21,720,296	$ 225	95,857,811	(74,137,740)
Ending balance (in shares) at Dec. 31, 2015		2,257,718
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)	0
Common stock and warrants issued for cash during August 2016 and February 2015, at $6.40 and $24.00 per unit, respectively, net of offering costs	$ 4,625,955	$ 111	4,625,844
Common stock and warrants issued for cash during August 2016 and February 2015, at $6.40 and $24.00 per unit, respectively, net of offering costs (in shares)		1,110,000
Stock based compensation	1,228,987	$ 0	1,228,987
Stock based compensation (in shares)		0
Common stock issued through controlled equity offering, in 2016 at an average price of $10.00 per share, and 2014 at $36.80 per share	$ 642,210	$ 8	642,202
Common stock issued through controlled equity offering, in 2016 at an average price of $10.00 per share, and 2014 at $36.80 per share (in shares)	77,141	77,141
Net loss	$ (22,085,702)			(22,085,702)
Ending Balance at Dec. 31, 2016	$ 6,131,746	$ 344	$ 102,354,844	$ (96,223,442)
Ending balance (in shares) at Dec. 31, 2016		3,444,859

Consolidated Statements of Sha6

Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares	Dec. 31, 2016	Aug. 31, 2016	Feb. 28, 2015	Dec. 31, 2014
Offer and Sale
Common stock issued through controlled equity offering (in usd per share)	$ 10			$ 36.80
Common stock and warrants issued for cash
Common stock and warrants issued for cash (in usd per share)		$ 6.40	$ 24

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net loss	$ (22,085,702)	$ (12,790,814)	$ (9,377,533)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	75,114	36,193	47,656
Accrued Interest on CIRM award	1,311,836	133,905	0
(Gain) loss on disposal of assets	0	0	(4)
Change in fair value of warrant liability	(3,812,398)	(2,925,258)	(529,774)
Financing expense	498,520	88,939	62,683
Stock-based compensation	1,228,987	916,028	654,260
Changes in assets and liabilities:
Other assets	5,940	422,448	(9,097)
Supplies for clinical trials	(221,545)	(2,209,192)	(227,097)
Deposits	2,220,766	(3,657,913)	(339,259)
Accounts payable	125,363	805,320	(644,587)
Accrued liabilities	788,677	140,943	425,950
Net cash used in operating activities	(19,864,442)	(19,039,401)	(9,936,802)
Cash flows from investing activities:
Purchase of property and equipment	(4,015)	(169,750)	(28,975)
Proceeds from sale of property and equipment	0	0	400
Net cash used in investing activities	(4,015)	(169,750)	(28,575)
Cash flows from financing activities:
Proceeds from exercise of stock options	0	6,750	1,045,000
Proceeds from exercise of warrants	208,750	0	0
Deferred financing costs	(44,711)	(15,041)	0
Proceeds from CIRM award	1,500,000	4,000,000	0
Proceeds from issuance of common stock and warrants, net of offering costs	6,345,868	14,599,627	0
Proceeds from issuance of common stock through controlled equity offering	691,187	0	4,496,322
Net cash provided by financing activities	8,701,094	18,591,336	5,541,322
Decrease in cash and cash equivalents	(11,167,363)	(617,815)	(4,424,055)
Cash and cash equivalents, beginning of period	22,604,481	23,222,296	27,646,351
Cash and cash equivalents, end of period	11,437,118	22,604,481	23,222,296
Supplemental cash flows disclosures:
Interest expense paid	0	0	0
Income taxes paid	0	0	0
Supplemental non-cash financing disclosures:
Deferred offering costs included in accounts payable	$ 55,505	$ 0	$ 0

Nature of Organization (Planned

Nature of Organization (Planned Principal Operations Have Not Commenced)	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Organization (Planned Principal Operations Have Not Commenced)	Nature of Organization (Planned Principal Operations Have Not Commenced) ImmunoCellular Therapeutics, Ltd. (the Company) is seeking to develop and commercialize new therapeutics to fight cancer using the immune system. These consolidated financial statements include the Company’s wholly owned subsidiaries, ImmunoCellular Bermuda, Ltd. in Bermuda and ImmunoCellular Therapeutics (Ireland) Limited and ImmunoCellular Therapeutics (Europe) Limited in Ireland, that were formed during 2014. The Company has been primarily engaged in the acquisition of certain intellectual property, together with development of its immunotherapy product candidates and the recent clinical testing activities for one of its immunotherapy product candidates, and has not generated any recurring revenues. The Company has begun phase 3 testing of its lead product candidate, ICT-107. The Company has two other product candidates, ICT -140 and ICT -121 , both with investigational new drug (IND) applications active at the US Food and Drug Administration (FDA). Currently, the Company has suspended development of ICT -140 until the Company has either secured a partner for the program or sufficient financial resources to complete the ICT -107 phase 3 program. Additionally, the Company has acquired the rights to technology for the development of certain Stem-to-T-cell immunotherapies for the treatment of cancer. The Company has incurred operating losses and, as of December 31, 2016 , the Company had an accumulated deficit of $96,223,442 . The Company expects to incur significant research, development and administrative expenses before any of its products can be launched and recurring revenues generated. The Company's activities are subject to significant risks and uncertainties, including the failure of any of the Company's product candidates to achieve clinical success or to obtain regulatory approval. Additionally, it is possible that other companies with competing products and technology might obtain regulatory approval ahead of the Company. The Company will need significant amounts of additional funding in order to complete the development of any of its product candidates and the availability and terms of such funding cannot be assured.

Summary of Significant Accounti

Summary of Significant Accounting Policies and Going Concern	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Going Concern	Summary of Significant Accounting Policies and Going Concern Principles of Consolidation – The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation. Basis of presentation and going concern - The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Since inception, the Company has been engaged in research and development activities and has not generated any cash flows from operations. Through December 31, 2016 , the Company has incurred accumulated losses of $96,223,442 and as of December 31, 2016 , the Company had $11,437,118 of cash. The Company expects that its costs will increase in 2017 primarily to fund the phase 3 trial of ICT-107, and that it will not have enough cash resources to fund the business for at least the next 12 months. Successful completion of the Company’s research and development activities, and its transition to attaining profitable operations, is dependent upon obtaining additional financing. Additional financing may not be available on acceptable terms or at all. If the Company issues additional equity securities to raise funds, the ownership percentage of existing stockholders would be reduced. New investors may demand rights, preferences or privileges senior to those of existing holders of common stock. If the Company cannot raise funds, it might be forced to make substantial reductions in the on-going clinical trials thereby damaging the Company's reputation in the biotech and medical communities which could adversely affect the Company’s ability to implement its business plan and its viability. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. These financial statements do not include any adjustment that might result from the outcome of this uncertainty. The Company's plans to improve its liquidity require the Company to raise additional financing through the issuance of financial instruments such as equity and warrants or through the receipt of grants and awards. Additionally, the Company is undertaking an evaluation of strategic alternatives, which may include a potential merger, consolidation, reorganization or other business combination, as well as the sale of the Company or the Company's assets. While the Company evaluates strategic alternatives, it plans to continue to advance its research and development strategies, including the execution of the phase 3 trial of ICT-107. Cash and cash equivalents— The Company considers all highly liquid instruments with an original maturity of 90 days or less at acquisition to be cash equivalents. As of December 31, 2016 and December 31, 2015 , the Company had $3,462,617 and $21,818,229 , respectively, of certificates of deposit and U.S. Government issued notes. The Company places its cash and cash equivalents with various banks and U.S. Governmental Agencies in order to maintain insurance on all of its investments. Property and Equipment —Property and equipment are stated at cost and depreciated using the straight-line methods based on the estimated useful lives (generally three to five years) of the related assets. Computer and computer equipment are depreciated over three years. Management continuously monitors and evaluates the realizability of recorded long-lived assets to determine whether their carrying values have been impaired. The Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the nondiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. Any impairment loss is measured by comparing the fair value of the asset to its carrying amount. Repairs and maintenance costs are expensed as incurred. Research and Development Expenses —Research and development expenses consist of costs incurred for direct research and development and are expensed as incurred. Supplies - Supplies are stated at the lower of cost or market, with cost determined by the first-in, first-out basis and consist of items that will be used in the Company’s ongoing clinical trials. Management analyzes historical and prospective usage to estimate obsolescence and did not record any reserve for obsolescence during the years ended December 31, 2016, 2015 and 2014. Additionally, management has estimated supply usage in the next twelve months to determine the balance sheet classification between current and non-current. Stock Based Compensation— The Company records the cost for all share-based payment transactions in the Company’s consolidated financial statements. Stock option grants issued to employees, officers and directors were valued using the Black-Scholes pricing model. Fair value was estimated at the date of grant using the following weighted-average grant date assumptions: Year Year Year Risk-free interest rate 1.31 % 1.80 % 1.64 % Expected dividend yield None None None Expected life 5.73 years 6.48 years 5.21 years Expected volatility 82.2 % 93.40 % 90.6 % Expected forfeitures — % — % — % The weighted-average grant-date fair value of options granted during the year ended December 31, 2016 , 2015 and 2014 was $8.00 , $13.60 and $38.40 , respectively. The risk-free interest rate used is based on the implied yield currently available in U.S. Treasury securities at maturity with an equivalent term. The Company has not declared or paid any dividends and does not currently expect to do so in the future. The expected term of options represents the period that our stock-based awards are expected to be outstanding and was determined based on projected holding periods for the remaining unexercised shares. Consideration was given to the contractual terms of our stock-based awards, vesting schedules and expectations of future employee behavior. The expected volatility is based upon the historical volatility of the Company’s common stock. Forfeitures are accounted for when they occur. The Company’s stock price volatility and option lives involve management’s best estimates, both of which impact the fair value of the option calculated and, ultimately, the expense that will be recognized over the life of the option. When options are exercised, the Company's policy is to issue reserved but previously unissued shares of common stock to satisfy share option exercises. As of December 31, 2016 , the Company had 19,462,422 shares of authorized and unreserved common stock. As of December 31, 2016 , the Company had 199,197 shares of common stock reserved for its stock option plan. No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for all net deferred tax assets. Income Taxes —The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. As of December 31, 2016 and 2015 , the Company fully reserved its deferred tax assets. The Company recognizes in its consolidated financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. As of December 31, 2016 and 2015 , the Company had no unrecognized tax benefits and as such, no liability, interest or penalties were required to be recorded. The Company does not expect this to change significantly in the next twelve months. The Company has determined that its main taxing jurisdictions are the United States of America and the State of California. The Company is not currently under examination by any taxing authority nor has it been notified of a pending examination. The Company’s tax returns are generally no longer subject to examination for the years before December 31, 2011 for the state and December 31, 2012 for the federal taxing authority. During 2014, the Company licensed the non-U.S. rights to a significant portion of its intellectual property to its Bermuda-based subsidiary for approximately $11.0 million . The fair value of the intellectual property rights was determined by an independent third party. The proceeds from this sale represent a gain for U.S. tax purposes and were offset by current year losses and net operating loss carryforwards. However, the Internal Revenue Service, or the IRS, or the California Franchise Tax Board, or the CFTB, could challenge the valuation of the intellectual property rights and assess a greater valuation, which would require the Company to utilize a portion, or all, of its available net operating losses. If an IRS or a CFTB valuation exceeds the available net operating losses, the Company would incur additional income taxes. The Company’s ability to use its net operating losses is subject to the limitations of IRS Section 382, as well as expiration of federal and state net operating loss carryforwards. Fair Value of Financial Instruments —The carrying amounts reported in the balance sheets for cash, cash equivalents, and accounts payable approximate their fair values due to their quick turnover. The fair value of warrant liability is estimated using the Binomial Lattice option valuation model. Fair value for financial reporting is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company utilizes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: Level 1 - quoted prices in active markets for identical assets or liabilities Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 - inputs that are unobservable (for example cash flow modeling inputs based on assumptions) Warrant liabilities represent the only financial assets or liabilities recorded at fair value by the Company. The fair value of warrant liabilities are determined based on Level 1 or Level 3 inputs (See Note 6). Reverse Stock Split - On November 18, 2016, the Company effected a one-for-forty reverse stock split of its common stock through an amendment to its amended and restated certificate of incorporation (the “COI Amendment”). As of the effective time of the reverse stock split, every forty shares of the Company’s issued and outstanding common stock were converted into one issued and outstanding share of common stock, without any change in par value per share. The reverse stock split affected all shares of the Company’s common stock outstanding immediately prior to the effective time of the reverse stock split, as well as the number of shares of common stock available for issuance under the Company’s equity incentive plans and outstanding warrants. No fractional shares were issued as a result of the reverse stock split. Stockholders who would otherwise have been entitled to receive a fractional share received cash payments in lieu thereof. In addition, the COI Amendment reduced the number of authorized shares of common stock to 25.0 million . As the par value per share of the Company’s common stock remained unchanged at $0.0001 per share, a total of $8,805 was reclassified from common stock to additional paid-in capital during 2016. All references to shares of common stock and per share data for all periods presented in the accompanying financial statements and notes thereto have been adjusted to reflect the reverse stock split on a retroactive basis. Use of Estimates —The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these consolidated financial statements. The following critical accounting policies affect the Company’s more significant judgments and estimates used in the preparation of these financial statements: Stock-Based Compensation - Stock-based compensation expense is estimated as of the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which generally equals the vesting period, based on the number of awards that are expected to vest. Estimating the fair value for stock options requires judgment, including the expected term of our stock options, volatility of the Company’s stock, expected dividends, risk-free interest rates over the expected term of the options and the expected forfeiture rate. In connection with performance based programs, the Company makes assumptions principally related to the number of awards that are expected to vest after assessing the probability that certain performance criteria will be met. Warrant liability - The fair value of the Company's derivative warrants that are not traded on the NYSE MKT is estimated using the Binomial Lattice option valuation model. The use of the Binomial Lattice option valuation model requires estimates including the volatility of the Company’s stock, risk-free rates over the expected term of warrants and early exercise of the options. Basic and Diluted Net Loss per Common Share —Basic and diluted net loss per common share are computed based on the weighted average number of common shares outstanding plus the pre-funded warrants (see Note 6) that were substantially paid for at the time of issuance. Common share equivalents (which consist of options and warrants other than the pre-funded warrants) are excluded from the computation of diluted net loss per share for the years ended December 31, 2016 , 2015 and 2014 , since the effect would be antidilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted net loss per share, totaled 1,871,222 , 485,524 and 652,725 shares at December 31, 2016 , 2015 and 2014 , respectively. Recently Issued Accounting Standards —In August 2014, the FASB issued ASU No. 2014-15, which applies to entities that have substantial doubt about their ability to continue as a going concern. This update requires management to perform interim and annual assessments of the probability about the entity’s ability to remain as a going concern for a period of one year from the date the financial statements are issued. Depending on management’s conclusions about the entity’s ability to remain as a going concern, the entity must make certain disclosures in its financial statements. This ASU is effective for annual periods ending after December 15, 2016. The adoption of this ASU did not have a material impact on the Company’s consolidated results of operations, financial condition or liquidity. In February 2016, the FASB issued ASU No. 2016-02, which requires lessees to recognize in the balance sheets, a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term (the lease asset). For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This ASU is effective for fiscal years beginning after December 15, 2018. The adoption of this ASU is not expected to have a material impact on the Company’s consolidated results of operations, finance condition or liquidity. In March 2016, the FASB issued ASU No. 2016-09, which simplifies some of the rules relating to the accounting for stock options. Among other items, this update permits entities to account for stock option forfeitures when they occur unlike the current practice that requires estimation of forfeitures at the time off issuance. This ASU is effective for annual periods beginning after December 15, 2016, and early adoption is permitted. The Company early adopted this ASU as of 2016, which has not had a material impact on the Company’s consolidated results of operations, financial condition or liquidity. Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force) and the Securities Exchange Commission (the SEC) did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment consist of the following: December 31, December 31, Computers $ 70,960 $ 66,945 Research equipment 305,066 305,066 376,026 372,011 Accumulated depreciation (266,203 ) (191,089 ) $ 109,823 $ 180,922 All of the research equipment is held by the Company's vendors. Depreciation expense was $75,114 , $36,193 and $47,656 for the years ended December 31, 2016 , 2015 and 2014 , respectively.

Related-Party Transactions

Related-Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related-Party Transactions	Related-Party Transactions Cedars-Sinai Medical Center License Agreement Dr. John Yu, the Company's founder and member of the Company's Board of Directors, is a neurosurgeon at Cedars-Sinai Medical Center (Cedars-Sinai). On May 13, 2015, the Company entered into an Amended and Restated Exclusive License Agreement (the Amended License Agreement) with Cedars-Sinai to amend and restate the terms of the Original License Agreement. Pursuant to the Amended License Agreement, the Company acquired an exclusive, worldwide license from Cedars-Sinai to certain patent rights and technology developed in the course of research performed at Cedars-Sinai into the diagnosis of diseases and disorders in humans and the prevention and treatment of disorders in humans utilizing cellular therapies, including dendritic cell-based vaccines for brain tumors and other cancers and neurodegenerative disorders. Under the Amended License Agreement, the Company will have exclusive rights to, among other things, develop, use, manufacture, sell and grant sublicenses to the licensed technology. The Company has agreed to pay Cedars-Sinai specified milestone payments related to the development and commercialization of ICT-107, ICT-121 and ICT-140. Among other milestone payments, the Company will be required to pay to Cedars-Sinai specified milestone payments upon commencement of the first phase 3 clinical trial (see licensing fees below) for the Company’s first product and upon first commercial sale of the Company’s first product. If both of these milestones are met, the required milestone payments will total $1.1 million . The Company will pay Cedars-Sinai single digit percentages of gross revenues from the sales of products and high-single digit to low-double digit percentages of the Company’s sublicensing income based on the licensed technology. During 2016, the Company incurred $100,000 of licensing fees to Cedars-Sinai in connection with the commencement of the phase 3 clinical trial of ICT-107. The Company did not incur any licensing fees to Cedars-Sinai during the two years ended December 31, 2015 . The Amended License Agreement will terminate on a country-by-country basis on the expiration date of the last-to-expire licensed patent right in each such country. Either party may terminate the Amended License Agreement in the event of the other party’s material breach of its obligations under the Agreement if such breach remains uncured 60 days after such party’s receipt of written notice of such breach. Cedars-Sinai may also terminate the Amended License Agreement upon 30 days written notice to the Company that a required payment by the Company to Cedars-Sinai under the Amended License Agreement is delinquent. The Company has also entered into various sponsored research agreements with Cedars-Sinai. For the years ended December 31, 2016, 2015 and 2014, the Company incurred research expenses from Cedars-Sinai of $0 , $55,200 , and $140,508 respectively. As of December 31, 2016 , Cedars-Sinai is not performing any research activities on behalf of the Company.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies SEC Investigation The Company has agreed in principle with the staff of the SEC on a proposed settlement framework related to an investigation principally of a former Chief Executive Officer of the Company involving conduct between November 2011 and August 2012 regarding the publication of articles without disclosing that they were paid for by the Company or investor relations firms hired by the Company. The Company would consent to the entry of an administrative order requiring that it cease and desist from any future violations of Sections 5, 17(a), and 17(b) of the Securities Act of 1933, as amended, and Section 10(b) of the Securities Exchange Act of 1934, as amended, subject to approval by the Commissioners of the SEC, without admitting or denying any allegations. The proposed settlement also involves the adoption of certain corporate governance amendments to the Company's policies and practices, in particular as it relates to the retention of investor relations and public relations firms. The proposed settlement is contingent upon execution of a formal offer of settlement and approval by the Commissioners of the SEC, neither of which can be assured. Based upon the settlement framework with the staff of the SEC, the Company has not accrued and does not currently expect to accrue a liability related to this matter. However, any final settlement must be approved by the Commission. If the Commission does not approve the settlement, the Company may need to enter into further discussions with the SEC to resolve the investigated matters on different terms and conditions. As a result, there can be no assurance as to the final terms of any settlement including its financial impact or any future adjustment to the financial statements. Commitments In an effort to expand the Company’s intellectual property portfolio to use antigens to create personalized vaccines, the Company has entered into various intellectual property and research agreements. Those agreements are long-term in nature and are discussed below. In addition to the vendors described below, the Company has deposits with other vendors. Sponsored Research Agreements Novella Clinical LLC On June 30, 2015, the Company entered into a Master Clinical Research Services Agreement with Novella Clinical LLC (Novella Clinical) to conduct the phase 3 registration trial of ICT-107. Novella Clinical is a full-service, global clinical research organization providing clinical trial services to small and mid-sized oncology companies. Novella Clinical will supervise the trial in the United States, Europe and Canada and will recruit approximately 542 patients with newly diagnosed glioblastoma. As of December 31, 2016 and 2015, the Company has deposits of $2,068,241 and $3,725,772 respectively, with Novella Clinical. Since the trial is not expected to be completed within the next twelve months, $1,725,772 this amount is included in deposits and reflected as a non-current asset on the December 31, 2016 balance sheet while $342,469 is reflected as a current asset. The Company may terminate this agreement upon 60 days’ notice. Licensing Agreements The John Hopkins University Licensing Agreement On February 23, 2012, the Company entered into an Exclusive License Agreement, effective as of February 16, 2012, with The John Hopkins University (JHU) under which it received an exclusive, world-wide license to JHU’s rights in and to certain intellectual property related to mesothelin-specific cancer immunotherapies. The Company is advancing a cancer vaccine program using JHU and other intellectual property according to commercially reasonable development timeline. If successful and a product ultimately is registered, the Company will either sell the product directly or via a third-party partnership. Pursuant to the License Agreement, the Company agreed to pay an upfront licensing fee in the low hundreds of thousands of dollars, payable half in cash and half in shares of its common stock in two tranches, within 30 days of the effective date of the License Agreement and upon issuance of the first U.S. patent covering the subject technology. Annual minimum royalties or maintenance fees increase over time and range from low tens of thousands to low hundreds of thousands of dollars. In addition, the Company has agreed to pay milestone license fees upon completion of specified milestones, totaling single digit millions of dollars if all milestones are met. Royalties based on a low single digit percentage of net sales are also due on direct sales, while third party sublicensing payments will be shared at a low double digit percentage. The Company and JHU each have termination rights that include termination for any reason and for reasons relating to specific performance or financial conditions. Effective September 24, 2013, the Company entered into an Amendment No. 1 to the Exclusive License Agreement that updated certain milestones. Effective August 7, 2015, the Company entered into a Second Amendment to Exclusive License Agreement that amended certain sections of the License Agreement and further updated certain milestones. California Institute of Technology On September 9, 2014, the Company entered into an Exclusive License Agreement with the California Institute of Technology (Caltech) under which the Company acquired exclusive rights to novel technology for the development of certain Stem-to-T-cell immunotherapies for the treatment of cancers. Pursuant to the License Agreement, the Company agreed to pay a one time license fee, a minimum annual royalty based on a low single digit percentage of net revenues and an annual maintenance fee in the low tens of thousands of dollars. In addition, the Company has agreed to make certain milestone payments upon completion of specified milestones. Cedars-Sinai Medical Center In connection with the Cedars-Sinai Medical Center License Agreement, the Company has certain commitments as described in Note 4. Manufacturing PharmaCell B.V. In March 2015, the Company entered into an Agreement for GMP manufacturing of ICT-107 with PharmaCell B.V. (PharmaCell), pursuant to which PharmaCell will provide contract manufacturing services for the European production of ICT-107, a dendritic cell immunotherapy for the treatment of newly diagnosed glioblastoma. The Company will pay for manufacturing services performed by PharmaCell under the Agreement pursuant to statements of work entered into from time to time. The Company may unilaterally terminate the Agreement upon 90 days’ written notice to PharmaCell, or 30 days’ written notice in the event of a clinical hold or other suspension or early termination of a clinical trial. PharmaCell may terminate the Agreement in certain circumstances upon 90 days’ written notice to the Company. Either party may terminate the Agreement in the event of the other party’s insolvency or for the other party’s material breach of its obligations under the Agreement if such breach remains uncured after 30 days of receiving written notice of such breach. Absent early termination, the Agreement will continue until all services under applicable statements of work have been completed. PCT, LLC On June 11, 2015, the Company entered into a Services Agreement with PCT, LLC, a Caladrius Company (PCT), a subsidiary of Caladrius Biosciences, Inc. Pursuant to the terms of the Agreement, PCT will provide current good manufacturing practice (cGMP) services for the phase 3 manufacture of ICT-107. PCT will provide, among other things, a controlled environment room on a semi-dedicated basis and qualified personnel to conduct runs as the parties mutually agree in writing and schedule. PCT’s facilities are registered with the FDA for testing; packaging; processing; storage; labeling and distribution of Peripheral Blood stem and Somatic Cell therapy products, and maintain cGMP-compliant quality systems. The Company has agreed to pay monthly fees in connection with the use of a controlled environment room on a semi-dedicated basis and monthly fees for PCT personnel performing services under the Agreement. Services to be performed under the Agreement terminate on the earlier of (i) December 31, 2018, (ii) the date the parties mutually agree, (iii) at any time following the earlier of the one year anniversary of the date on which the Company notifies PCT that services in the semi-dedicated controlled environment room are to commence (August 1, 2016), on the last day of the month following at least 120 days’ written notice from the Company to PCT, or (iv) the last day of the month following at least 60 days’ written notice from the Company to PCT that the Company has received a clinical hold issued by the FDA ordering the Company to suspend clinical trials for ICT-107. Either party may terminate the Agreement in the event of the other party’s insolvency or for the other party’s material breach of its obligations under the Agreement if such breach remains uncured after 30 days of receiving written notice of such breach. Summary of Employment Agreements The Company has employment agreements with its management that provide for base salary, bonus, grants of stock options and restricted stock and severance. The aggregate base salary payable to this group is approximately $830,000 and the potential bonus is approximately $231,000 . During the years ended December 31, 2016 , 2015 and 2014 , the Company issued an aggregate of 825,000 , 1,125,000 and 317,500 stock options to its management at a weighted average exercise price of $13.20 , $23.20 and $53.60 , respectively. All of the aforementioned stock options vest over a period of 4 years . Additionally, during the years ended December 31, 2016 and 2015, the Company issued 3,375 and 6,500 restricted shares of the Company's common stock that will vest over a period of 2 years . Certain members of management are also entitled to severance payments in the event of a change in control or termination without cause. The aggregate potential severance payments to management is approximately $420,000 . This amount does not reflect the severance and other related accruals to a former CEO of approximately $700,000 whose employment ended on December 31, 2016, and is reflected in the accrued compensation and benefits on the balance sheet. These members of management would also be entitled to COBRA for various periods of time. Operating Lease The Company entered into a lease for new office space effective June 15, 2013 and continuing through August 31, 2016 at an initial monthly rental of $8,063 . During 2016, the Company extended this lease through August 31, 2017, at a monthly rental of $8,554 . Rent expense was approximately $108,000 , $102,000 and $99,000 for the years ended December 31, 2016 , 2015 and 2014 , respectively

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Shareholders' Equity	Shareholders’ Equity On November 16, 2015, the Company amended its Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 149,000,000 to 249,000,000 . The stockholders of the Company approved the increase in authorized shares at a special meeting of the stockholders held on November 16, 2015. On November 18, 2016, upon the stockholder approval of a one-for-forty reverse stock split and the amendment to the Company’s amended and restated certificate of incorporation, the number of authorized shares of common stock was reduced to 25,000,000 . Common Stock In August 2016, the Company raised approximately $6.6 million (after deducting underwriting discount and offering expenses) from the initial sale of 863,750 shares of the Company's common stock, 881,250 base warrants to purchase shares of common stock at an exercise price of $7.68 per share, and 311,250 pre-funded warrants to purchase shares of common stock at an exercise price of $0.40 per share. The underwriters partially exercised their option to purchase additional shares and warrants and purchased an additional 37,500 shares of the Company's common stock at a price of $6.00 per share and 111,965 pre-funded warrants to purchase shares of common stock at an exercise price of $0.40 per warrant. The pre-funded warrants have a term of ten years , and the base warrants have a term of five years from the date of issuance. The base warrants also provide for a weighted average adjustment to the exercise price if the Company issues, or is deemed to issue, additional shares of common stock at a price per share less than the effective price of the warrants, subject to certain exceptions (see "Warrant Liability" below). Due to the potential variability of their exercise price, the base warrants do not qualify for equity treatment. The pre-funded warrants were substantially paid for at the time of the offering and have an exercise price of $0.40 per share. The pre-funded warrants qualify for equity treatment. Through December 31, 2016, 208,750 pre-funded warrants were exercised and resulted in proceeds to the Company of $83,500 . In February 2015, the Company raised approximately $14.5 million (after commissions and offering expenses) from the sale of 666,250 shares of common stock and warrants to purchase 466,375 shares of common stock at an exercise price of $26.40 per share, to various investors in an underwritten public offering. Each unit, consisting of one share of common stock and 0.7 warrant, was priced at $24.00 . The warrants have a term of five years from the date of issuance. The warrants also provide for a weighted-average adjustment to the exercise price if the Company issues or is deemed to issue additional shares of common stock at a price per share less than the then effective price of the warrants, subject to certain exceptions (see “Warrants and Warrant Liabilities” below.) Controlled Equity Offering On April 18, 2013, the Company entered into a Controlled Equity Offering SM Sales Agreement (the Sales Agreement) with Cantor Fitzgerald & Co., as agent (Cantor), pursuant to which the Company may offer from time to time through Cantor, shares of our common stock having an aggregate offering price of up to $25.0 million (of which $17.0 million was initially registered for offer and sale). Under the Sales Agreement, Cantor may sell shares by any method permitted by law and deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act, as amended, including sales made directly on the NYSE MKT, on any other existing trading market for our common stock or to or through a market maker. The Company may instruct Cantor not to sell shares if the sales cannot be effected at or above the price designated by us from time to time. The Company is not obligated to make any sales of the shares under the Sales Agreement. The offering of shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. Cantor will receive a commission rate of 3% of the aggregate gross proceeds from each sale of shares and the Company has agreed to provide Cantor with customary indemnification and contribution rights. The Company will also reimburse Cantor for certain specified expenses in connection with entering into the Sales Agreement. On April 22, 2013, NYSE MKT approved the listing of 264,831 shares of our common stock in connection with the Sales Agreement. As of September 21, 2015, the registration statement previously filed with the SEC to facilitate the sale of registered shares of the Company's common stock under the Controlled Equity Offering expired. The Company filed a new registration statement with the SEC that was declared effective on January 19, 2016 to facilitate the sale of additional shares under the Controlled Equity Offering. Under the terms of the prospectus, the Company may sell up to $15,081,494 of the Company's common stock through the aforementioned Controlled Equity Offering. Pursuant to Instruction I.B.6 to Form S-3 (the Baby Shelf Rules), the Company may not sell more than the equivalent of one-third of its public float during any 12 consecutive months so long as the Company's public float is less than $75.0 million . During the year ended December 31, 2016 , the Company sold 77,141 shares of our common stock under the Sales Agreement that resulted in net proceeds to the Company of approximately $691,187 of which $48,977 represented the recovery of deferred offering costs that had been incurred as of December 31, 2015. As of December 31, 2016, the Company had approximately $14.3 million available to be sold under the Sales Agreement. Stock Options In February 2005, the Company adopted an Equity Incentive Plan (Plan). Pursuant to the Plan, a committee appointed by the Board of Directors may grant, at its discretion, qualified or nonqualified stock options, stock appreciation rights and may grant or sell restricted stock to key individuals, including employees, nonemployee directors, consultants and advisors. Option prices for qualified incentive stock options (which may only be granted to employees) issued under the plan 100% of the fair market value of the common stock on the date the option is granted (unless the option is granted to a person who, at the time of grant, owns 10% of the total combined voting power of all classes of stock of the Company; in which case the option price may not be 110% of the fair market value of the common stock on the date the option is granted). Option prices for nonqualified stock options issued under the Plan are at the discretion of the committee and may be equal to, greater or less than fair market value of the common stock on the date the option is granted. The options vest over periods determined by the Board of Directors and are exercisable no later than ten years from date of grant (unless they are qualified incentive stock options granted to a person owning more than 10% of the total combined voting power of all classes of stock of the Company, in which case the options are exercisable no later than five years from date of grant). Initially, the Company reserved 150,000 shares of common stock for issuance under the Plan which was subsequently increased to 300,000 shares. Options to purchase 110,846 common shares have been granted under the Plan and are outstanding as of December 31, 2016 . Additionally, 6,500 shares of restricted common stock have been granted to management and 1,000 shares of restricted common stock have been granted to members of the Company's board of directors. The plan expired in January 2016. On March 11, 2016, the Company's Board of Directors adopted the 2016 Equity Incentive Plan (the 2016 Plan) and reserved 250,000 shares of common stock for issuance under the 2016 Plan. The 2016 Plan was approved by the Company's stockholders at its 2016 Annual Meeting of Stockholders. During the year ended December 31, 2016, the Company's Board of Directors granted 48,444 stock options and 7,862 restricted stock units to certain directors, officers and employees. The options have an exercise price equal to the closing stock price on the date of grant. The stock options vest over a period of four years and the restricted stock units vest over a period of two years . The following table summarizes stock option activity for the Company during the three years ended December 31, 2016 : Options Weighted Average Exercise Price Weighted Average Contractual Term Aggregate Intrinsic Value Outstanding December 31, 2013 261,667 $ 54.80 Granted 13,678 $ 51.20 Exercised (15,601 ) $ 94.40 Forfeited or expired (26,875 ) $ 43.20 Outstanding December 31, 2014 232,869 $ 53.20 Granted 46,075 $ 21.60 Exercised (1,250 ) $ 10.80 Forfeited or expired (9,697 ) $ 70.40 Outstanding December 31, 2015 267,997 $ 47.20 Granted 48,444 $ 11.61 Exercised — $ — Forfeited or expired (153,776 ) $ 40.63 Outstanding December 31, 2016 162,665 $ 43.11 6.30 $ — Vested or expected to vest at December 31, 2015 102,020 As of December 31, 2016 , the total unrecognized compensation cost related to unvested stock options amounted to $727,856 , which will be amortized over the weighted-average remaining requisite service period of approximately 11 months . Warrants Accounted for As Equity In connection with the January 2012 underwritten public offering, the Company issued to the investors warrants to purchase 118,618 shares of the Company’s common stock at $56.40 per share. The warrants had a term of five years from the date of issuance. These warrants qualify for equity treatment since they do not have any provisions that would require the Company to redeem them for cash or that would result in an adjustment to the number of warrants. As of December 31, 2016 , warrants to purchase 35,454 shares of the Company’s common stock were outstanding. In January 2017 the remaining warrants expired (See Subsequent Events Note 10). In connection with the October 2012 underwritten public offering, the Company issued to the investors warrants to purchase 112,500 shares of the Company’s common stock at $106.00 per share. The warrants have a term of five years from the date of issuance. These warrants qualify for equity treatment since they do not have any provisions that would require the Company to redeem them for cash or that would result in an adjustment to the number of warrants. As of December 31, 2016 , warrants to purchase 111,119 shares of the Company’s common stock remain outstanding relating to this public offering. In connection with the August 2016 underwritten public offering, the Company issued 311,250 pre-funded warrants to purchase shares of common stock to certain investors. These pre-funded warrants were substantially paid for at the time of issuance, have a term of ten years from the date of issuance and an exercise price of $0.40 per share. During 2016, pre-funded warrants to purchase 208,750 shares of common stock were exercised and pre-funded warrants to purchase 102,500 shares of common stock remain outstanding as of December 31, 2016. These pre-funded warrants qualify for equity treatment since they do not have any provisions that would require the Company to redeem them for cash or that would result in an adjustment to either the exercise price or the number of shares that would be issuable upon exercise. Warrants Accounted for as Liabilities The Company’s warrant liability is adjusted to fair value each reporting period and is influenced by several factors, including but not limited to, the price of the Company’s common stock as of the balance sheet date. On December 31, 2016 , the price per share of Company’s common stock was $2.05 per share compared to $14.40 per share at December 31, 2015 and $29.20 per share at December 31, 2014 . In connection with the sale of Preferred stock in May 2010, the Company issued warrants to purchase 33,750 shares of the Company’s common stock at an exercise price of $100.00 per share. Of the total proceeds from the May 2010 preferred stock sale, $5,710,500 was allocated to the freestanding warrants associated with the units based upon the fair value of these warrants determined under the Black Scholes option pricing model. The warrants contain a provision whereby the warrant may be settled for cash in connection with a change of control with a private company. Due to their potential cash settlement, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. The warrant liability is adjusted to fair value each reporting period and any change in value is recognized in the statement of operations. Prior to 2011 , the Company concluded that the Black-Scholes method of valuing the price adjustment feature does not materially differ from the valuation of such warrants using the Monte Carlo or binomial lattice simulation models, and therefore, the use of the Black-Scholes valuation model was considered a reasonable method to value the warrants. The assumptions used in the Black Scholes model for determining the initial fair value of the warrants were as follows: (i) dividend yield of 0% ; (ii) expected volatility of 102% , (iii) risk-free interest rate of 2.50% , and (iv) contractual life of five years . Effective January 1, 2011, the Company determined that it was more appropriate to value the warrants using a binomial lattice simulation model. For the years ended December 31, 2014 and 2015, the Company recorded a credit to other income of $260,781 and $7,746 respectively. During 2015, the remaining warrants expired. In February 2011, the Company completed a common stock private placement and issued warrants to purchase 70,467 shares of the Company’s common stock at $90.00 per share. The warrants contained a provision whereby the warrant exercise price would be decreased in the event that certain future common stock issuances are made at a price less than $62.00 . Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. As a result of the January 2012, October 2012, and February 2015 financings and shares sold through the Company's Controlled Equity Offering, the exercise price of the warrants was adjusted to $57.60 and the number of warrants was proportionately increased to 91,670 net of exercises. The warrant liability is adjusted to fair value each reporting period, and any change in value is recognized in the statement of operations. The Company initially valued these warrants using a binomial lattice simulation model assuming (i) dividend yield of 0.0% ; (ii) expected volatility of 146.0% ; (iii) risk free rate of 1.96% and (iv) expected term of five years . Based upon those calculations, the Company allocated $2,476,790 of the private placement proceeds to the freestanding warrants. The lattice simulation model used by the Company at December 31, 2015 assumed (i) dividend yield of 0.0% ; (ii) expected volatility of 148.0% ; (iii) risk free rate of 0.31% and (iv) expected term of 1.14 years . For the years ended December 31, 2014 and 2015, the Company recorded a credit to other expense of $268,993 and $678,912 respectively. The remaining warrants expired on February 24, 2016. The Company did not record a credit or charge to change in fair value of warrant liability in other income during 2016. In connection with the February 2015 underwritten public offering, the Company issued to the investors warrants to purchase 466,369 shares of the Company’s common stock at $26.40 per share. The warrants contain a provision whereby the warrant exercise price would be decreased in the event that certain future common stock issuances are made at a price less than $26.40 . Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. During 2016, the exercise price of these warrants was adjusted to $20.00 to reflect the shares sold under the Company's controlled equity offering and the August 2016 public offering. The Company initially valued these warrants using a binomial lattice simulation model assuming (i) dividend yield of 0% ; (ii) expected volatility of 97% ; (iii) risk free rate of 1.53% and (iv) expected term of five years . Based upon these calculations, the Company allocated $4,197,375 of the underwritten public offering to the freestanding warrants. As of December 31, 2015, the Company revalued the warrants using the binomial lattice simulation model assuming (i) dividend yield of 0% ; (ii) expected volatility of 91% ; (iii) risk free rate of 1.56% and (iv) expected term of 4.11 years . For the year ended December 31, 2015, the Company recorded a credit to other income of $ 2,238,600 . As of December 31, 2016, the Company revalued the warrants using the binomial lattice simulation model assuming (i) dividend yield of 0% ; (ii) expected volatility of 89% ; (iii) risk free rate of 1.5% and expected term of 3.11 years . For the year ended December 31, 2016, the Company recorded a credit to other income of $2,024,611 . As of December 31, 2016, the carrying value of the warrant liability is $76,952 . In connection with the August 2016 underwritten public offering, the Company issued to the investors 993,115 warrants to purchase shares of the common stock with an initial exercise price of $7.68 per share. The warrants contain a provision whereby the warrant exercise price would be proportionately decreased in the event that future common stock issuances are made at a price less than $7.68 per share. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. These warrants are traded on the NYSE MKT (symbol IMUC.WS). The Company initially valued these warrants using the closing price on August 12, 2016 at $2.30 , which was the first day the warrants were traded on the NYSE MKT. Accordingly, the Company allocated 2,284,395 of the total proceeds from the August 2016 offering to the base warrants. As of December 31, 2016, the warrants were valued using the last trading price of the year at $0.50 , accordingly, the warrant liability was adjusted to $496,608 and the Company recorded a credit to other income of $1,787,787 . The below table summarizes the warrant liability activity for the years ended December 31, 2016 , 2015 and 2014 . The gain included in net loss is reflective of several changes in the assumptions used in the computation of fair value, including the decrease in the Company's stock price, during the years ended December 31, 2016 , 2015 and 2014 . 2016 2015 2014 Beginning Balance, January 1 $ 1,958,775 $ 597,719 $ 1,064,810 Issuance of warrants and effect of repricing 2,427,183 4,286,314 62,683 Exercise of warrants — — — (Gain) or loss included in earnings (3,812,398 ) (2,925,258 ) (529,774 ) Transfers in and/or out of Level 3 — — — Ending Balance December 31, $ 573,560 $ 1,958,775 $ 597,719

California Institute of Regener

California Institute of Regenerative Medicine Award	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
California Institute of Regenerative Medicine Award	California Institute of Regenerative Medicine Award On September 18, 2015 , the Company received an award in the amount of $19,919,449 from the California Institute of Regenerative Medicine (CIRM) to partially fund the Company’s phase 3 trial of ICT-107. The award provided for a $4,000,000 project initial payment, which was received during the fourth quarter of 2015, and up to $15,919,449 in future milestone payments that are primarily dependent on patient enrollment in the ICT-107 phase 3 trial. In August 2016, the Company and CIRM modified the award such that the Company received an additional $1.5 million initial payment. The total amount of the award and other award conditions remain unchanged. Under the terms of the CIRM award, the Company is obligated to share future ICT-107 related revenue with CIRM. The percentage of revenue sharing is dependent on the amount of the award received by the Company and whether the revenue is from product sales or license fees. The maximum revenue sharing amount the Company may be required to pay to CIRM is equal to nine (9) times the total amount awarded and received by the Company. The Company has the option to decline any and all amounts awarded by CIRM. As an alternative to revenue sharing, the Company has the option to convert the award to a loan, which such option the Company must exercise on or before ten (10) business days after the FDA notifies the Company that it has accepted the Company’s application for marketing authorization. In the event the Company exercises its right to convert the award to a loan, it will be obligated to repay the loan within ten (10) business days of making such election, including interest at the rate of the three-month LIBOR rate ( 0.92% as of December 31, 2016 ) plus 25% per annum. Since the Company may be required to repay some or all of the amounts awarded by CIRM, the Company plans to account for this award as a liability rather than revenue. If the Company was to lose this funding, it may be required to delay, postpone, or cancel its clinical trials or otherwise reduce or curtail its operations unless it is able to obtain adequate financing for its clinical trials from additional sources. As of December 31, 2016 , the Company has accrued interest of $1,445,741 , which is included in the CIRM liability on the Consolidated Balance Sheets.

401(k) Profit Sharing Plan

401(k) Profit Sharing Plan	12 Months Ended
	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
401(k) Profit Sharing Plan	401(k) Profit Sharing Plan The Company has adopted a Profit Sharing Plan that qualifies under Section 401(k) of the Internal Revenue Code. Contributions to the plan are at the Company’s discretion. The Company did not make any matching contributions during the years ended December 31, 2016 and 2015 .

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Deferred taxes represent the net tax effects of the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes. Temporary differences result primarily from the recording of tax benefits of net operating loss carry forwards and stock-based compensation. As of December 31, 2016 , the Company has an insufficient history to support the likelihood of ultimate realization of the benefit associated with the deferred tax asset. Accordingly, a valuation allowance has been established for the full amount of the net deferred tax asset. The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes as follows: 2016 2015 2014 Income tax benefit at the federal statutory rate (34 )% (34 )% (34 )% State income tax benefit, net of federal tax benefit (6 )% (6 )% (6 )% Change in fair value of warrant liability 7 % 8 % 2 % Change in valuation allowance for deferred tax assets 35 % 32 % 38 % Other (2 )% — % — % Total — % — % — % Deferred taxes consisted of the following: December 31, December 31, December 31, Net operating loss carryforwards $ 27,267,545 $ 20,091,036 $ 16,302,000 Stock-based compensation 3,090,903 2,599,308 2,191,000 Less valuation allowance (30,358,448 ) (22,690,344 ) (18,493,000 ) Net deferred tax asset $ — $ — $ — The valuation allowance increased by $7,668,104 , $4,197,344 and $712,739 during the years ended December 31, 2016 , 2015 and 2014 , respectively. As of December 31, 2016 , the Company had federal and California income tax net operating loss carryforwards of approximately $68.2 million . These net operating losses will begin to expire in taxable years 2027 through 2036 and 2017 through 2036 , respectively, unless previously utilized. Section 382 of the Internal Revenue Code can limit the amount of net operating losses which may be utilized if certain changes to a company’s ownership occur. As of December 31, 2016, the Company has not experienced a change in ownership as defined by Section 382 of the Internal Revenue Code, based on a revised analysis completed by management. Management estimated that the Company has not incurred any limitations on its ability to utilize its net operating losses under Section 382 of the Internal Revenue Code as a result of its February 2015 and August 2016 financings. During the fourth quarter of 2014 , the Company licensed the non-U.S. rights to a significant portion of its intellectual property to its Bermuda-based subsidiary for approximately $11 million . The fair value of the intellectual property rights was determined by an independent third party. The proceeds from this sale represent a gain for U.S. tax purposes and were offset by current year losses and net operating loss carryforwards. However, the Internal Revenue Service, or the IRS, or the California Franchise Tax Board, or the CFTB, could challenge the valuation of the intellectual property rights and assess a greater valuation, which would require the Company to utilize a portion, or all, of its available net operating losses. If an IRS or a CFTB valuation exceeds the available net operating losses, the Company would incur additional income taxes. The Company’s ability to use its net operating losses is subject to the limitations of IRS Section 382, as well as expiration of federal and state net operating loss carryforwards.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Warrant Expiration On January 12, 2017, warrants to purchase 35,464 shares of the Company's common stock issued in connection with the January 2012 underwritten public offering expired unexercised. See additional discussion in Note 6.

Summary of Significant Accoun18

Summary of Significant Accounting Policies and Going Concern (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation – The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
Basis of presentation and going concern	Basis of presentation and going concern - The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Since inception, the Company has been engaged in research and development activities and has not generated any cash flows from operations. Through December 31, 2016 , the Company has incurred accumulated losses of $96,223,442 and as of December 31, 2016 , the Company had $11,437,118 of cash. The Company expects that its costs will increase in 2017 primarily to fund the phase 3 trial of ICT-107, and that it will not have enough cash resources to fund the business for at least the next 12 months. Successful completion of the Company’s research and development activities, and its transition to attaining profitable operations, is dependent upon obtaining additional financing. Additional financing may not be available on acceptable terms or at all. If the Company issues additional equity securities to raise funds, the ownership percentage of existing stockholders would be reduced. New investors may demand rights, preferences or privileges senior to those of existing holders of common stock. If the Company cannot raise funds, it might be forced to make substantial reductions in the on-going clinical trials thereby damaging the Company's reputation in the biotech and medical communities which could adversely affect the Company’s ability to implement its business plan and its viability. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. These financial statements do not include any adjustment that might result from the outcome of this uncertainty. The Company's plans to improve its liquidity require the Company to raise additional financing through the issuance of financial instruments such as equity and warrants or through the receipt of grants and awards. Additionally, the Company is undertaking an evaluation of strategic alternatives, which may include a potential merger, consolidation, reorganization or other business combination, as well as the sale of the Company or the Company's assets. While the Company evaluates strategic alternatives, it plans to continue to advance its research and development strategies, including the execution of the phase 3 trial of ICT-107.
Cash and cash equivalents	Cash and cash equivalents— The Company considers all highly liquid instruments with an original maturity of 90 days or less at acquisition to be cash equivalents. As of December 31, 2016 and December 31, 2015 , the Company had $3,462,617 and $21,818,229 , respectively, of certificates of deposit and U.S. Government issued notes. The Company places its cash and cash equivalents with various banks and U.S. Governmental Agencies in order to maintain insurance on all of its investments.
Property and Equipment	Property and Equipment —Property and equipment are stated at cost and depreciated using the straight-line methods based on the estimated useful lives (generally three to five years) of the related assets. Computer and computer equipment are depreciated over three years. Management continuously monitors and evaluates the realizability of recorded long-lived assets to determine whether their carrying values have been impaired. The Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the nondiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. Any impairment loss is measured by comparing the fair value of the asset to its carrying amount. Repairs and maintenance costs are expensed as incurred.
Research and Development Expenses	Research and Development Expenses —Research and development expenses consist of costs incurred for direct research and development and are expensed as incurred.
Supplies	Supplies - Supplies are stated at the lower of cost or market, with cost determined by the first-in, first-out basis and consist of items that will be used in the Company’s ongoing clinical trials. Management analyzes historical and prospective usage to estimate obsolescence and did not record any reserve for obsolescence during the years ended December 31, 2016, 2015 and 2014. Additionally, management has estimated supply usage in the next twelve months to determine the balance sheet classification between current and non-current.
Stock Based Compensation	Stock Based Compensation— The Company records the cost for all share-based payment transactions in the Company’s consolidated financial statements. Stock option grants issued to employees, officers and directors were valued using the Black-Scholes pricing model. Stock-Based Compensation - Stock-based compensation expense is estimated as of the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which generally equals the vesting period, based on the number of awards that are expected to vest. Estimating the fair value for stock options requires judgment, including the expected term of our stock options, volatility of the Company’s stock, expected dividends, risk-free interest rates over the expected term of the options and the expected forfeiture rate. In connection with performance based programs, the Company makes assumptions principally related to the number of awards that are expected to vest after assessing the probability that certain performance criteria will be met. The risk-free interest rate used is based on the implied yield currently available in U.S. Treasury securities at maturity with an equivalent term. The Company has not declared or paid any dividends and does not currently expect to do so in the future. The expected term of options represents the period that our stock-based awards are expected to be outstanding and was determined based on projected holding periods for the remaining unexercised shares. Consideration was given to the contractual terms of our stock-based awards, vesting schedules and expectations of future employee behavior. The expected volatility is based upon the historical volatility of the Company’s common stock. Forfeitures are accounted for when they occur. The Company’s stock price volatility and option lives involve management’s best estimates, both of which impact the fair value of the option calculated and, ultimately, the expense that will be recognized over the life of the option. When options are exercised, the Company's policy is to issue reserved but previously unissued shares of common stock to satisfy share option exercises.
Income Taxes	Income Taxes —The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. As of December 31, 2016 and 2015 , the Company fully reserved its deferred tax assets. The Company recognizes in its consolidated financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. As of December 31, 2016 and 2015 , the Company had no unrecognized tax benefits and as such, no liability, interest or penalties were required to be recorded. The Company does not expect this to change significantly in the next twelve months. The Company has determined that its main taxing jurisdictions are the United States of America and the State of California. The Company is not currently under examination by any taxing authority nor has it been notified of a pending examination. The Company’s tax returns are generally no longer subject to examination for the years before December 31, 2011 for the state and December 31, 2012 for the federal taxing authority. During 2014, the Company licensed the non-U.S. rights to a significant portion of its intellectual property to its Bermuda-based subsidiary for approximately $11.0 million . The fair value of the intellectual property rights was determined by an independent third party. The proceeds from this sale represent a gain for U.S. tax purposes and were offset by current year losses and net operating loss carryforwards. However, the Internal Revenue Service, or the IRS, or the California Franchise Tax Board, or the CFTB, could challenge the valuation of the intellectual property rights and assess a greater valuation, which would require the Company to utilize a portion, or all, of its available net operating losses. If an IRS or a CFTB valuation exceeds the available net operating losses, the Company would incur additional income taxes. The Company’s ability to use its net operating losses is subject to the limitations of IRS Section 382, as well as expiration of federal and state net operating loss carryforwards.
Fair Value of Financial Instruments	Fair Value of Financial Instruments —The carrying amounts reported in the balance sheets for cash, cash equivalents, and accounts payable approximate their fair values due to their quick turnover. The fair value of warrant liability is estimated using the Binomial Lattice option valuation model. Fair value for financial reporting is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company utilizes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows: Level 1 - quoted prices in active markets for identical assets or liabilities Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 - inputs that are unobservable (for example cash flow modeling inputs based on assumptions) Warrant liabilities represent the only financial assets or liabilities recorded at fair value by the Company. The fair value of warrant liabilities are determined based on Level 1 or Level 3 inputs (See Note 6).
Use of Estimates	Use of Estimates —The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these consolidated financial statements.
Warrant Liability	Warrant liability - The fair value of the Company's derivative warrants that are not traded on the NYSE MKT is estimated using the Binomial Lattice option valuation model. The use of the Binomial Lattice option valuation model requires estimates including the volatility of the Company’s stock, risk-free rates over the expected term of warrants and early exercise of the options.
Basic and Diluted Net Loss per Common Share	Basic and Diluted Net Loss per Common Share —Basic and diluted net loss per common share are computed based on the weighted average number of common shares outstanding plus the pre-funded warrants (see Note 6) that were substantially paid for at the time of issuance. Common share equivalents (which consist of options and warrants other than the pre-funded warrants) are excluded from the computation of diluted net loss per share for the years ended December 31, 2016 , 2015 and 2014 , since the effect would be antidilutive.
Recently Issued Accounting Standards	Recently Issued Accounting Standards —In August 2014, the FASB issued ASU No. 2014-15, which applies to entities that have substantial doubt about their ability to continue as a going concern. This update requires management to perform interim and annual assessments of the probability about the entity’s ability to remain as a going concern for a period of one year from the date the financial statements are issued. Depending on management’s conclusions about the entity’s ability to remain as a going concern, the entity must make certain disclosures in its financial statements. This ASU is effective for annual periods ending after December 15, 2016. The adoption of this ASU did not have a material impact on the Company’s consolidated results of operations, financial condition or liquidity. In February 2016, the FASB issued ASU No. 2016-02, which requires lessees to recognize in the balance sheets, a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term (the lease asset). For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This ASU is effective for fiscal years beginning after December 15, 2018. The adoption of this ASU is not expected to have a material impact on the Company’s consolidated results of operations, finance condition or liquidity. In March 2016, the FASB issued ASU No. 2016-09, which simplifies some of the rules relating to the accounting for stock options. Among other items, this update permits entities to account for stock option forfeitures when they occur unlike the current practice that requires estimation of forfeitures at the time off issuance. This ASU is effective for annual periods beginning after December 15, 2016, and early adoption is permitted. The Company early adopted this ASU as of 2016, which has not had a material impact on the Company’s consolidated results of operations, financial condition or liquidity. Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force) and the Securities Exchange Commission (the SEC) did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Summary of Significant Accoun19

Summary of Significant Accounting Policies and Going Concern (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Schedule of Weighted Average Grant Date Assumptions	Fair value was estimated at the date of grant using the following weighted-average grant date assumptions: Year Year Year Risk-free interest rate 1.31 % 1.80 % 1.64 % Expected dividend yield None None None Expected life 5.73 years 6.48 years 5.21 years Expected volatility 82.2 % 93.40 % 90.6 % Expected forfeitures — % — % — %

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Components of Property and Equipment	Property and equipment consist of the following: December 31, December 31, Computers $ 70,960 $ 66,945 Research equipment 305,066 305,066 376,026 372,011 Accumulated depreciation (266,203 ) (191,089 ) $ 109,823 $ 180,922

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Summary of Stock Options Activity	The following table summarizes stock option activity for the Company during the three years ended December 31, 2016 : Options Weighted Average Exercise Price Weighted Average Contractual Term Aggregate Intrinsic Value Outstanding December 31, 2013 261,667 $ 54.80 Granted 13,678 $ 51.20 Exercised (15,601 ) $ 94.40 Forfeited or expired (26,875 ) $ 43.20 Outstanding December 31, 2014 232,869 $ 53.20 Granted 46,075 $ 21.60 Exercised (1,250 ) $ 10.80 Forfeited or expired (9,697 ) $ 70.40 Outstanding December 31, 2015 267,997 $ 47.20 Granted 48,444 $ 11.61 Exercised — $ — Forfeited or expired (153,776 ) $ 40.63 Outstanding December 31, 2016 162,665 $ 43.11 6.30 $ — Vested or expected to vest at December 31, 2015 102,020
Summary of Carrying Value of Warrant Liability	The below table summarizes the warrant liability activity for the years ended December 31, 2016 , 2015 and 2014 . The gain included in net loss is reflective of several changes in the assumptions used in the computation of fair value, including the decrease in the Company's stock price, during the years ended December 31, 2016 , 2015 and 2014 . 2016 2015 2014 Beginning Balance, January 1 $ 1,958,775 $ 597,719 $ 1,064,810 Issuance of warrants and effect of repricing 2,427,183 4,286,314 62,683 Exercise of warrants — — — (Gain) or loss included in earnings (3,812,398 ) (2,925,258 ) (529,774 ) Transfers in and/or out of Level 3 — — — Ending Balance December 31, $ 573,560 $ 1,958,775 $ 597,719

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Reconciliation of Federal Statutory Rate	The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes as follows: 2016 2015 2014 Income tax benefit at the federal statutory rate (34 )% (34 )% (34 )% State income tax benefit, net of federal tax benefit (6 )% (6 )% (6 )% Change in fair value of warrant liability 7 % 8 % 2 % Change in valuation allowance for deferred tax assets 35 % 32 % 38 % Other (2 )% — % — % Total — % — % — %
Schedule of Deferred Tax Assets	Deferred taxes consisted of the following: December 31, December 31, December 31, Net operating loss carryforwards $ 27,267,545 $ 20,091,036 $ 16,302,000 Stock-based compensation 3,090,903 2,599,308 2,191,000 Less valuation allowance (30,358,448 ) (22,690,344 ) (18,493,000 ) Net deferred tax asset $ — $ — $ —

Nature of Organization (Plann23

Nature of Organization (Planned Principal Operations Have Not Commenced) (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 96,223,442	$ 74,137,740

Summary of Significant Accoun24

Summary of Significant Accounting Policies and Going Concern - Additional Information (Details)	Nov. 18, 2016shares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Mar. 11, 2016shares	Nov. 16, 2015shares	Dec. 31, 2013USD ($)
Accounting Policies [Abstract]
Accumulated deficit		$ 96,223,442	$ 74,137,740
Cash		11,437,118	22,604,481	$ 23,222,296			$ 27,646,351
Certificates of deposit		$ 3,462,617	$ 21,818,229
Property, Plant and Equipment [Line Items]
Weighted-average grant-date fair value of options granted (in usd per share) | $ / shares		$ 8	$ 13.60	$ 38.40
Shares authorized but unissued common stock (in shares) | shares		19,462,422
Common stock reserved (in shares) | shares		199,197			250,000
Tax benefit attributed to the stock-based compensation expense		$ 0
Unrecognized tax benefits, liability, penalties or interest accrued		$ 0	$ 0
Fair value of the intellectual property				$ 11,000,000
Reverse stock split ratio	0.025
Common stock, shares authorized (in shares) | shares	25,000,000	25,000,000	25,000,000	149,000,000		249,000,000
Common stock, par value (in usd per share) | $ / shares		$ 0.0001	$ 0.0001
Reclassified from common stock to APIC		$ 8,805
Shares excluded from the computation of diluted net loss per share (in shares) | shares		1,871,222	485,524	652,725
Computer Equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment		3 years
Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment		3 years
Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment		5 years

Summary of Significant Accoun25

Summary of Significant Accounting Policies and Going Concern - Schedule of Weighted Average Grant Date Assumptions (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Schedule of stock options grants
Risk-free interest rate	1.31%	1.80%	1.64%
Expected dividend yield	0.00%	0.00%	0.00%
Expected life	5 years 8 months 24 days	6 years 5 months 24 days	5 years 2 months 17 days
Expected volatility	82.20%	93.40%	90.60%
Expected forfeitures	0.00%	0.00%	0.00%

Property and Equipment - Compon

Property and Equipment - Components of Property and Equipment (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Components of Property and Equipment
Property and equipment, gross	$ 376,026	$ 372,011
Accumulated depreciation	(266,203)	(191,089)
Property and equipment, net	109,823	180,922
Computers
Components of Property and Equipment
Property and equipment, gross	70,960	66,945
Research equipment
Components of Property and Equipment
Property and equipment, gross	$ 305,066	$ 305,066

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 75,114	$ 36,193	$ 47,656

Related-Party Transactions (Det

Related-Party Transactions (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Related Party Transaction [Line Items]
Incurred research expenses	$ 19,105,727	$ 10,896,591	$ 5,969,182
Cedars-Sinai Medical Center License Agreement
Related Party Transaction [Line Items]
Future additional milestone payment	1,100,000
Incurred licensing fees	$ 100,000	0	0
Period contract breach remains uncured	60 days
Written notice period for termination	30 days
Incurred research expenses	$ 0	$ 55,200	$ 140,508

Commitments and Contingencies (

Commitments and Contingencies (Details)	Jun. 30, 2015patient	Jun. 15, 2013USD ($)	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares
Loss Contingencies [Line Items]
Discretionary cash bonus			$ 0	$ 0
Options, granted (in shares) | shares			48,444	46,075	13,678
Exercise option price (in usd per share) | $ / shares			$ 11.61	$ 21.60	$ 51.20
Accrued compensation and benefits			$ 1,109,864	$ 790,487
Lease monthly rent		$ 8,063	8,554
Operating lease rent expense			$ 108,000	$ 102,000	$ 99,000
Employee Stock Option
Loss Contingencies [Line Items]
Stock options, vesting period			4 years
Restricted Stock Units (RSUs)
Loss Contingencies [Line Items]
Stock options, vesting period			2 years
JHU
Loss Contingencies [Line Items]
Period within effective date of License Agreement			30 days
Employment Agreement With Management
Loss Contingencies [Line Items]
Base salary			$ 830,000
Discretionary cash bonus			231,000
Severance costs			$ 420,000
Employment Agreement With Management | Employee Stock Option
Loss Contingencies [Line Items]
Options, granted (in shares) | shares			825,000	1,125,000	317,500
Exercise option price (in usd per share) | $ / shares			$ 13.20	$ 23.20	$ 53.60
Stock options, vesting period			4 years
Employment Agreement With Management | Restricted Stock Units (RSUs)
Loss Contingencies [Line Items]
Stock options, vesting period			2 years
Restricted shares issued by the company (in shares) | shares			3,375	6,500
Novella Clinical
Loss Contingencies [Line Items]
Number of patients | patient	542
Deposits for clinical trial services			$ 2,068,241	$ 3,725,772
Termination notice period			60 days
Noncurrent assets | Novella Clinical
Loss Contingencies [Line Items]
Deposits for clinical trial services			$ 1,725,772
Current assets | Novella Clinical
Loss Contingencies [Line Items]
Deposits for clinical trial services			342,469
Former CEO
Loss Contingencies [Line Items]
Accrued compensation and benefits			$ 700,000

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Details)

Nov. 18, 2016shares

Apr. 18, 2014

Apr. 22, 2013shares

Aug. 31, 2016USD ($)$ / sharesshares

Feb. 28, 2015USD ($)$ / sharesshares

Oct. 31, 2012$ / sharesshares

Jan. 31, 2012$ / sharesshares

Feb. 28, 2011USD ($)$ / sharesshares

May 31, 2010USD ($)$ / sharesshares

Feb. 28, 2005shares

Dec. 31, 2016USD ($)$ / sharesshares

Dec. 31, 2016USD ($)$ / sharesshares

Dec. 31, 2015USD ($)$ / sharesshares

Dec. 31, 2014USD ($)$ / sharesshares

Dec. 31, 2010

Aug. 12, 2016$ / shares

Mar. 11, 2016shares

Jan. 19, 2016USD ($)

Nov. 16, 2015shares

Dec. 31, 2013shares

Apr. 18, 2013USD ($)

Class Of Stock [Line Items]

Common stock, shares authorized (in shares)

25,000,000

25,000,000

25,000,000

25,000,000

149,000,000

249,000,000

Reverse stock split ratio

0.025

Proceeds from issuance of common stock and warrants, net of offering costs | $

$ 6,345,868

$ 14,599,627

$ 0

Common stock issued through controlled equity offering (in shares)

77,141

Exercise price (in USD per share) | $ / shares

$ 57.60

$ 20

$ 20

Proceeds from the common stock private placement | $

$ 14,500,000

Price of units issued (in USD per share) | $ / shares

$ 24

Common stock reserved | $

$ 15,081,494

Proceeds from issuance of common stock | $

$ 344

$ 344

$ 225

Maximum public float | $

$ 75,000,000

Proceeds from issuance of common stock | $

691,187

Recovery of deferred offering costs | $

48,977

Available for sale under agreement | $

$ 14,300,000

$ 14,300,000

Percentage of fair market value of common stock

100.00%

Percentage of common stock voting rights held

10.00%

Minimum percentage of fair market value of common stock

110.00%

Option exercise period

10 years

Common stock, shares authorized under the plan (in shares)

150,000

300,000

300,000

Common stock, shares granted and outstanding (in shares)

162,665

162,665

267,997

232,869

261,667

Restricted shares and units granted (in shares)

6,500

Common stock reserved (in shares)

199,197

199,197

250,000

Shares purchasable through options granted (in shares)

48,444

46,075

13,678

Unrecognized compensation cost related to unvested stock options | $

$ 727,856

$ 727,856

Remaining requisite service period, weighted-average

11 months

Warrants exercisable period after initial issuance

5 years

Common stock shares purchasable in private placement per warrant (in shares)

91,670

Initial valuation of warrants | $

$ 2,476,790

Valuation allowance | $

$ 4,197,375

Closing share price (in USD per share) | $ / shares

$ 2.30

Public offering expenses | $

$ 1,787,787

Stock Compensation Plan

Class Of Stock [Line Items]

Common stock, shares granted and outstanding (in shares)

110,846

110,846

Restricted Stock Units (RSUs)

Class Of Stock [Line Items]

Restricted shares and units granted (in shares)

7,862

Stock options, vesting period

2 years

Employee Stock Option

Class Of Stock [Line Items]

Stock options, vesting period

4 years

Board Of Directors

Class Of Stock [Line Items]

Restricted shares and units granted (in shares)

1,000

January

Class Of Stock [Line Items]

Common stock shares purchasable in private placement per warrant (in shares)

35,454

35,454

October

Class Of Stock [Line Items]

Exercise price (in USD per share) | $ / shares

$ 106

Warrants exercisable period after initial issuance

5 years

Common stock shares purchasable in private placement per warrant (in shares)

111,119

111,119

February 2,011

Class Of Stock [Line Items]

Other income | $

$ 678,912

$ 268,993

February 2011 | Warranty Obligations

Class Of Stock [Line Items]

Exercise price (in USD per share) | $ / shares

$ 90

February 2011 | Previously Reported | Binomial Simulation

Class Of Stock [Line Items]

Dividend yield rate

0.00%

0.00%

Expected volatility rate

146.00%

148.00%

Risk-free interest rate

1.96%

0.31%

Contractual life

5 years

1 year 1 month 21 days

February 2,015

Class Of Stock [Line Items]

Dividend yield rate

0.00%

0.00%

Expected volatility rate

97.00%

91.00%

Risk-free interest rate

1.53%

1.56%

Contractual life

5 years

4 years 1 month 10 days

Other income | $

$ 2,238,600

February

Class Of Stock [Line Items]

Proceeds from the common stock private placement | $

$ 76,952

Dividend yield rate

0.00%

Expected volatility rate

89.00%

Risk-free interest rate

1.50%

Contractual life

3 years 1 month 10 days

Other income | $

$ 2,024,611

Cantor Fitzgerald & Co.

Class Of Stock [Line Items]

Common stock reserved | $

$ 25,000,000

Commission rate

3.00%

Maximum | February 2011

Class Of Stock [Line Items]

Exercise price (in USD per share) | $ / shares

$ 62

Qualified Incentive Stock Options

Class Of Stock [Line Items]

Option exercise period

5 years

Offer and Sale | Cantor Fitzgerald & Co.

Class Of Stock [Line Items]

Proceeds from issuance of common stock | $

$ 17,000,000

Common Stock

Class Of Stock [Line Items]

Common stock issued through controlled equity offering (in shares)

77,141

127,103

Exercise price (in USD per share) | $ / shares

$ 26.40

$ 56.40

$ 2.05

$ 2.05

$ 14.40

$ 29.20

Convertible units issued (in shares)

1

Warrant

Class Of Stock [Line Items]

Convertible units issued (in shares)

0.7

Warrant exercise term investor relations agreement

5 years

Preferred Stock

Class Of Stock [Line Items]

Proceeds from exercised warrants | $

$ 5,710,500

Preferred Stock | May

Class Of Stock [Line Items]

Exercise price (in USD per share) | $ / shares

$ 100

Other income | $

$ 7,746

$ 260,781

Preferred Stock | May | Binomial Simulation

Class Of Stock [Line Items]

Dividend yield rate

0.00%

Expected volatility rate

102.00%

Risk-free interest rate

2.50%

Contractual life

5 years

Private Placement

Class Of Stock [Line Items]

Common stock issued through controlled equity offering (in shares)

666,250

Amount of common stock purchasable by exercise of warrants (in shares)

466,375

112,500

118,618

Private Placement | Warranty Obligations

Class Of Stock [Line Items]

Amount of common stock purchasable by exercise of warrants (in shares)

70,467

Private Placement | Preferred Stock

Class Of Stock [Line Items]

Amount of common stock purchasable by exercise of warrants (in shares)

33,750

Public Offering

Class Of Stock [Line Items]

Common stock issued through controlled equity offering (in shares)

264,831

2015 Underwritten Public Offering

Class Of Stock [Line Items]

Amount of common stock purchasable by exercise of warrants (in shares)

466,369

Exercise price (in USD per share) | $ / shares

$ 26.40

Maxim Group, LLC

Class Of Stock [Line Items]

Amount of common stock purchasable by exercise of warrants (in shares)

993,115

Proceeds from the common stock private placement | $

$ 496,608

Common stock shares purchasable in private placement per warrant (in shares)

2,284,395

2,284,395

Maxim Group, LLC | Common Stock

Class Of Stock [Line Items]

Exercise price (in USD per share) | $ / shares

$ 6

Maxim Group, LLC | Warrant

Class Of Stock [Line Items]

Exercise price (in USD per share) | $ / shares

$ 0.40

Maxim Group, LLC | Underwritten Public Offering

Class Of Stock [Line Items]

Proceeds from issuance of common stock and warrants, net of offering costs | $

$ 6,600,000

Common stock issued through controlled equity offering (in shares)

863,750

Maxim Group, LLC | Underwritten Public Offering | Warrant

Class Of Stock [Line Items]

Exercise price (in USD per share) | $ / shares

$ 0.50

$ 0.50

Maxim Group, LLC | Over-Allotment Option

Class Of Stock [Line Items]

Common stock issued through controlled equity offering (in shares)

37,500

Maxim Group, LLC | Base Warrant

Class Of Stock [Line Items]

Amount of common stock purchasable by exercise of warrants (in shares)

881,250

Exercise price (in USD per share) | $ / shares

$ 7.68

Term of warrants

5 years

Maxim Group, LLC | Pre-funded Warrant

Class Of Stock [Line Items]

Amount of common stock purchasable by exercise of warrants (in shares)

311,250

Exercise price (in USD per share) | $ / shares

$ 0.40

Term of warrants

10 years

10 years

Warrants exercised (in shares)

208,750

Proceeds from exercised warrants | $

$ 83,500

Warrants outstanding (in shares)

102,500

102,500

Maxim Group, LLC | Pre-funded Warrant | Underwritten Public Offering

Class Of Stock [Line Items]

Amount of common stock purchasable by exercise of warrants (in shares)

111,965

Shareholders' Equity - Summary

Shareholders' Equity - Summary of Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Options
Options outstanding, Beginning Balance (in shares)	267,997	232,869	261,667
Options, granted (in shares)	48,444	46,075	13,678
Options exercised (in shares)	0	(1,250)	(15,601)
Options, Forfeited or expired (in shares)	(153,776)	(9,697)	(26,875)
Options outstanding, Ending Balance (in shares)	162,665	267,997	232,869
Options, Vested or expected to vest (in shares)	102,020
Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding, Beginning Balance (in USD per share)	$ 47.20	$ 53.20	$ 54.80
Weighted Average Exercise Price, Granted (in USD per share)	11.61	21.60	51.20
Weighted Average Exercise Price, Exercised (in USD per share)	0	10.80	94.40
Weighted Average Exercise Price, Forfeited or expired (in USD per share)	40.63	70.40	43.20
Weighted Average Exercise Price, Outstanding, Ending Balance (in USD per share)	43.11	$ 47.20	$ 53.20
Weighted Average Exercise Price, Vested or expected to vest (in USD per share)
Weighted Average Contractual Term and Aggregate Intrinsic Value
Weighted Average Contractual Term, Outstanding	6 years 3 months 20 days
Weighted Average Contractual Term, Vested or expected to vest
Aggregate Intrinsic Value, Outstanding	$ 0
Aggregate Intrinsic Value, Vested or expected to vest

Shareholders' Equity - Summar32

Shareholders' Equity - Summary of Warranty Liability Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Class of Warrant or Right [Roll Forward]
Beginning Balance	$ 1,958,775	$ 597,719	$ 1,064,810
Issuance of warrants and effect of repricing	2,427,183	4,286,314	62,683
Exercise of warrants	0	0	0
(Gain) or loss included in earnings	(3,812,398)	(2,925,258)	(529,774)
Transfers in and/or out of Level 3	0	0	0
Ending Balance	$ 573,560	$ 1,958,775	$ 597,719

California Institute of Regen33

California Institute of Regenerative Medicine Award (Details) - California Institute of Regenerative Medicine - USD ($)	Sep. 18, 2015	Aug. 31, 2016	Dec. 31, 2015	Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Proceeds from award received for project	$ 19,919,449
Proceeds from project initiation payment		$ 1,500,000	$ 4,000,000
Future milestone payments receivable				$ 15,919,449
Debt interest rate during period				25.00%
Accrued interest				$ 1,445,741
LIBOR
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Debt basis spread on variable rate				0.92%

401(k) Profit Sharing Plan (Det

401(k) Profit Sharing Plan (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Discretionary cash bonus	$ 0	$ 0

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Federal Statutory Rate (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income tax benefit at the federal statutory rate	(34.00%)	(34.00%)	(34.00%)
State income tax benefit, net of federal tax benefit	(6.00%)	(6.00%)	(6.00%)
Change in fair value of warrant liability	7.00%	8.00%	2.00%
Change in valuation allowance for deferred tax assets	35.00%	32.00%	38.00%
Other	(2.00%)	0.00%	0.00%
Total	0.00%	0.00%	0.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 27,267,545	$ 20,091,036	$ 16,302,000
Stock-based compensation	3,090,903	2,599,308	2,191,000
Less valuation allowance	(30,358,448)	(22,690,344)	(18,493,000)
Net deferred tax asset	$ 0	$ 0	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Increase in valuation allowance		$ 7,668,104	$ 4,197,344	$ 712,739
Income tax net operating loss carryforwards		$ 68,200,000
Proceeds from licensing intellectual property	$ 11,000,000

Subsequent Events (Details)

Subsequent Events (Details)	Jan. 12, 2017shares
Subsequent Event
Subsequent Event [Line Items]
Warrants issued (in shares)	35,464